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PMH23 National Institute of Mental Health, Washington, DC, USA
PMH24 None
PMH25 None
PMH26 Universiti Sains Malaysia, Penang, Malaysia
PMH27 Substance Abuse and Mental Health Services Agency, Bethesda, MD, 
USA
PMH28 Pﬁ zer Spain, Madrid, Spain
PMH29 Bristol-Myers Squibb, Madrid, Spain
PMH30 Servier Ireland, Dublin, Ireland
PMH31 Bristol Myers Squibb Pharmaceuticals Ltd., Uxbridge, UK
PMH32 Servier Hungary, Budapest, Hungary
PMH33 Bristol-Myers Squibb, Braine-l’Alleud, Belgium
PMH34 None
PMH35 Lundbeck SAS, ISSY les MouiIneaux, France
PMH36 BMS, Madrid, Spain
PMH37 Janssen-Cilag, Spain, Spain
PMH38 AstraZeneca UK Ltd., Luton, England
PMH39 Servier Polska Sp. z o.o., Warsaw, Poland
PMH40 Lundbeck Poland Sp z o.o., Warsaw, Poland
PMH41 Lundbeck, Issy-les-Moulineaux, France
PMH42 None
PMH43 Eli Lilly and Company, Bad Homburg, Germany
PMH44 AstraZeneca, Södertälje, Sweden
PMH45 Ortho-McNeil Janssen Scientiﬁ c Affairs, LLC, Bethesda, MD, USA
PMH46 None
PMH47 National Health Research Institutes, Jhunan County, Taiwan
PMH48 AstraZeneca, Budapest, Hungary
PMH49 None
PMH50 None
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PMH52 FIS PI08/90812, Madrid, Spain; BIOEF BIO09/EM/001, Bilbao, Spain
PMH53 None
PMH54 None
PMH55 AstraZeneca, Madrid, Spain
PMH56 None
PMH57 None
PMH58 Janssen Alzheimer Immunotherapy, Dublin, Ireland
PMH59 BristomMyersSquibb, Brussels, Belgium
PMH60 AstraZeneca, Brussels, Belgium
PMH61 Lundbeck SAS, Issy-les-Moulineaux, France
PMH62 None
PMH63 National Research Foundation (NRF), Pretoria, South Africa
PMH64 Lundbeck, Paris, France
PMH65 DAHTA@DIMDI, Cologne, Germany
PMH66 None
PMH67 None
PMH68 Janssen Cilag, Neuss, Germany
PMH69 Janssen Cilag, Neuss, Germany
PMH70 None
PMH71 ZonMw, The Hague, The Netherlands
PMH72 None
PMH73 None
PMS1 Takeda Pharmaceuticals International, Inc., Deerﬁ eld, IL, USA
PMS2 Amgen Inc., Thousand Oaks, CA, USA
PMS3 Medtronic, Tolochenaz, Switzerland
PMS4 UCB, Brussels, Belgium
PMS5 Alberta Health and Wellness grant from three pharmaceutical 





PMS10 Takeda Pharmaceuticals International, Inc., Deerﬁ eld, IL, USA
PMS11 Novartis Farma spa, Varese, Italy
PMS12 Heraeus Medical GmbH, Wehrheim, Germany
PMS13 Heraeus Medical GmbH, wehrheim, Germany
PMS14 None
PMS15 Novartis Pharma, Basel, Switzerland
PMS16 None
PMS17 Medtronic Spinal and Biologics, Memphis, TN, USA
PMS18 Roche S.p.A, Monza, Italy
PMS19 None
PMS20 BMS, Seoul, South Korea
PMS21 Amgen Canada, Burlington, ON, Canada
PMS22 AMGEN, Neuilly sur Seine, France
PMS23 Amgen, Vienna, Austria
PMS24 Amgen Dompè S.p.A., Milano, Italy
PMS25 None
PMS26 None
PMS27 Ministry of Health, Labor and Welfare, Tokyo, Japan
PMS28 Abbott Laboratories, Madrid, Spain
PMS29 Amgen, Vienna, Austria
PMS30 North-West University, Potchefstroom, South Africa
PMS31 Pﬁ zer, Collegeville, PA, USA
PMS32 Medtronic Italy, Milan, Italy
PMS33 Productos Roche S.A. de C.V., México, Mexico
PMS34 Schering-Plough Corp, Welwyn Garden City, UK
PMS35 Eli Lilly and Company, Indianapolis, IN, USA
PMS36 None
PMS37 Bristol-Myers Squibb, Uxbridge, UK
PMS38 Roche México, México, Mexico
PMS39 None
PMS40 Amgen, Zug, Switzerland
PMS41 Amgen Europe, Zug, Switzerland
PMS42 UCB, Brussels, Belgium
PMS43 Roche Oy, Espoo, Finland
PMS44 None
PMS45 None
PMS46 Eli Lilly and Company, Indianapolis, IN, USA
PMS47 Eli Lilly and Company, Indianapolis, IN, USA
PMS48 None
PMS49 None
PMS50 Merck & Co., Whitehouse Station, NJ, USA
PMS51 Nycomed Pharma, Madrid, Spain
PMS52 Merck & Co., Inc., Whitehouse Station, NJ, USA
PMS53 Roche Hellas SA., Athens, Greece
PMS54 Servier Hungaria Kft, Budapest, Hungary; Centre for Public Affairs 




PMS58 Eli Lilly and Company, Indianapolis, IN, USA
PMS59 None
PMS60 None
PMS61 Merck Sharp & Dohme, Madrid, Spain
PMS62 UCB, Brussels, Belgium
PMS63 None
PMS64 Charles University, Prague, Czech Republic
PMS65 Genentech, South San Francisto, CA, USA
PMS66 Finnish Medicines Agency, Helsinki, Finland
PMS67 Ministry of Health, Labor and Welfare, Tokyo, Japan
PMS68 Merck & Co., Inc., Whitehouse Station, NJ, USA
PMS69 PFSA, Boulogne, France
PMS70 PFSA, Boulogne Cedex, France
PMS71 Bristol-Myers Squibb, Uxbridge, UK
PMS72 Bayer, São Paulo, Brazil
PMS73 Thomson Reuters, Cambridge, MA, USA
PMS74 None





PND1 Teva Pharmaceuticals, Kansas City, MO, USA
PND2 None
PND3 None
PND4 National Institute for Health Technlogy Assessment (IATS)—Brazil, 
Porto Alegre, Brazil
PND5 Eisai, Woodcliff Lake, NJ, USA
PND6 National Institute for Health Technlogy Assessment (IATS), NPq, Brazil, 
Porto Alegre, Brazil
PND7 Biogen Idec, Wellesley, MA, USA
PND8 Covidien, Zurich, Switzerland
PND9 None
PND10 Novartis, São Paulo, Brazil; Novartis, Flohram Park, NJ, USA
PND11 MerckSerono UK, Feltham, UK
PND12 University Claude Bernard Lyon 1, Lyon, France
PND13 None
PND14 Biogen Idec, Vienna, Austria
PND15 None
PND16 Janssen-Cilag, Neuss, Germany
PND17 Lundbeck SAS, Issy-Les-Moulineaux, France
PND18 None
PND19 Biogen Idec GmbH, Munich, Germany
PND20 Glaxo SmithKline, Zeist, The Netherlands
PND21 UCB MEXICO, Mexico D.F., Mexico
PND22 None
PND23 None
PND24 BiogenIdec, Cambridge, MA, USA
PND25 Biogen Idec, Vienna, Austria
PND26 UCB Pharma S.A., Brussels, Belgium
PND27 Abbott Product Operations AG, Allschwil, Switzerland
PND28 UCB S.A., Brussels, Belgium
PND29 MSD Sweden, Sollentuna, Sweden




PND34 Teva Neuroscience, Kansas City, MO, USA
PND35 None
PND36 Teva Neuroscience, Kansas City, MO, USA
PND37 Novartis Pharma, Barcelona, Spain
PND38 None
PND39 Merck Serono, S.A., Geneva, Switzerland
PND40 University Claude Bernard Lyon 1, Lyon, France
PND41 Grunenthal GmbH, Aachen, Germany
PND42 None
PND43 Lundbeck Canada, Montreal, QC, Canada
PND44 None
PND45 Cyberonics, Zaventem, Belgium
PND46 Merck Serono, S.A., Geneva, Switzerland
PND47 Merck Sharp & Dohme, Madrid, Spain
PND48 Allergan, Inc., Irvine, CA, USA
PRS1 Abbott Laboratories, Montreal, QC, Canada
PRS2 Abbott Laboratories, Montreal, QC, Canada
PRS3 GlaxoSmithKline R&D, Greenford, UK
PRS4 Pﬁ zer, Spain, Madrid, Spain
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PRS6 The Netherlands Asthma Foundation, Amersfoort, The Netherlands
PRS7 NYCOMED Sp. z o. o., Warsaw, Poland
PRS8 NYCOMED Sp. z o. o., Warsaw, Poland
PRS9 GlaxoSmithKline, London, England
PRS10 None
PRS11 GSK, Hong Kong, China
PRS12 None
PRS13 Novartis Pharma, Barcelona, Spain
PRS14 Covidien, Zurich, Switzerland
PRS15 Covidien, Zurich, Switzerland
PRS16 AstraZeneca, Budapest, Hungary
PRS17 Nycomed S.p.a, Milan, Italy
PRS18 AstraZeneca Nordic, Södertälje, Sweden





PRS24 Dutch Government Ministry of Health, Den Haag, The Netherlands
PRS25 Boehringer Ingelheim Italy, Milan, Italy
PRS26 Mantecorp, São Paulo, Brazil
PRS27 Nycomed BV, Hoofddorp, The Netherlands
PRS28 GSK, Mexico D.F., Mexico
PRS29 GSK, Mexico D.F., Mexico
PRS30 None
PRS31 GlaxoSmithKline Russia, Moscow, Russia
PRS32 GlaxoSmithKline Russia, Moscow, Russia
PRS33 Bayer Healthcare, Barcelona, Spain
PRS34 AstraZeneca Nordic, Södertälje, Sweden
PRS35 Chiesi España, Barcelona, Spain
PRS36 None
PRS37 AstraZeneca, Macclesﬁ eld, UK
PRS38 None
PRS39 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgeﬁ eld, CT, USA; Pﬁ zer 
Inc., New York, NY, USA
PRS40 Pﬁ zer B.V., Capelle a/d IJssel, The Netherlands
PRS41 Merck Sharp & Dohme, Madrid, Spain
PRS42 Canadian Institutes for Health Research, Ottawa, ON, Canada; AllerGen 
Network Centre for Excellence, Hamilton, ON, Canada
PRS43 Novartis, Origgio, Italy
PRS44 Essex Pharma, Munich, Germany
PRS45 None





PRS50 Forest Research Institute, Jersey City, NJ, USA
PRS51 None
PR1 None
PR2 Top Institute Pharma, Leiden, The Netherlands
PR3 None
PR4 None
PSS1 Nestlé Nutrition Institute, Vevey, Switzerland
PSS2 Janssen-Cilag GmbH, Neuss, Germany
PSS3 Basilea Pharmaceutica S.r.l., Milano, Italy
PSS4 Basilea Pharmaceutica, Basel, Switzerland
PSS5 alcon france, rueil-malmaison, France
PSS6 Abbott Scandinavia AB, Solna, Sweden
PSS7 None
PSS8 ALCON, Puurs, Belgium
PSS9 Alcon France, Rueil-Malmaison, France
PSS10 APA Parafricta Ltd., Newport Pagnell, UK
PSS11 None
PSS12 Novartis (Hellas) S.A.C.I., Athens, Greece
PSS13 Allergan, Bucks, UK
PSS14 Janssen-Cilag, Kiev, Ukraine
PSS15 None
PSS16 Nestlé Nutrition Institute, Vevey, Switzerland
PSS17 Nestlé Nutrition Institute, Vevey, Switzerland
PSS18 Nestlé Nutrition Institute, Vevey, Switzerland
PSS19 Eye Hospital, Rotterdam, The Netherlands
PSS20 Novartis Pharma, Basel, Switzerland
PSS21 Astellas Pharma Europe Ltd., Staines, UK
PSS22 GSK Biologicals, Wavre, Belgium
PSS23 None
PSS24 Alcon, Puurs, Belgium
PSS25 Alcon Laboratories, Puurs, Belgium
PSS26 Intendis GmbH, Berlin, Germany
PSS27 Eau Thermale Avene, Lavaur, France
PSS28 Abbott France, Rungis, France
PSS29 L’Oreal Research International, Paris, France
PSS30 None
PSS31 Alcon France, Rueil-Malmaison, France
PSS32 None
PSS33 Janssen-Cilag GmbH, Neuss, Germany
PSS34 None
PSS35 Basilea Pharmaceutica, Basel, Switzerland
PSS36 Alcon France, Rueil-Malmaison, France
PSS37 Alcon France, Rueil-Malmaison, France
PSS38 Pﬁ zer Ltd., Walton, UK
PSY1 Roche Spain, Madrid, Spain
PSY2 None
PSY3 EISAI, San Donato Milanese, Italy
PSY4 Schering Plough, Kenilworth, NJ, USA
PSY5 Novartis Pharmaceuticals UK Limited, Frimley, UK
PSY6 Shire Human Genetic Therapies, Danderyd, Sweden
PSY7 Novo Nordisk Pharma, Warsaw, Poland
PSY8 Janssen Cilag GmbH, Neuss, Germany
PSY9 CSL Behring, Esplugues de Llobregat, Spain
PSY10 Grünenthal GmbH, Aachen, Germany
PSY11 Janssen-Cilag, São José dos Campos, Brazil
PSY12 Vifor AG, Villars-sur-Glane, Switzerland; Vifor Pharma International, 
Glattbrugg, Switzerland
PSY13 Pﬁ zer, Sollentuna, Sweden
PSY14 Eli Lilly and Company, Indianapolis, IN, USA
PSY15 Pﬁ zer, São Paulo, Brazil
PSY16 Eli Lilly and Company, Indianapolis, IN, USA
PSY17 None
PSY18 CSL Behring, Esplugues de Llobregat, Spain
PSY19 Eli Lilly and Company, Indianapolis, IN, USA
PSY20 GlaxoSmithKline, Uxbridge, UK; Human Genome Sciences, Rockville, 
MD, USA
PSY21 Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
PSY22 None
PSY23 None
PSY24 Bristol-Myers Squibb México, Mexico, Mexico
PSY25 Amgen (Spain), Barcelona, Sri Lanka
PSY26 None
PSY27 Amgen SA/NV, Brussels, Belgium
PSY28 Bayer Healthcare, Barcelona, Spain
PSY29 None
PSY30 Medtronic Italia, Sesto San Giovanni, Italy
PSY31 Merck Canada Inc., Montreal, QC, Canada
PSY32 GlaxoSmithKline, Dublin, Ireland
PSY33 None
PSY34 Grünenthal GmbH, Aachen, Germany
PSY35 Eli Lilly and Company, Indianapolis, IN, USA
PSY36 Baxter Healthcare, Zurich, Switzerland
PSY37 Janssen-Cilag, São Paulo, Brazil
PSY38 Schering-Plough Corp, Welwyn Garden City, UK
PSY39 CVZ (Dutch Health Care Insurance Board), Diemen, The Netherlands
PSY40 Pﬁ zer Spain, Madrid, Spain
PSY41 Janssen-Cilag, Bogota, Colombia
PSY42 Janssen-Cilag Farmaceutica Ltda., São Paulo, Brazil
PSY43 Roche Farmacêutica Química, Portugal, Amadora, Portugal
PSY44 Gruenenthal GmbH, Aachen, Germany
PSY45 Pﬁ zer, Tadworth, UK
PSY46 None
PSY47 Grunenthal Ltd., Stokenchurch, UK
PSY48 Johnson & Johnson, São Paulo, Brazil
PSY49 Verein zur Förderung der Rehabilitationsforschung in Hamburg, 
Mecklenburg-Vorpommern und Schleswig-Holstein e.V., Lübeck, 
Germany
PSY50 None
PSY51 Grünenthal GmbH, Aachen, Germany
PSY52 Johnson & Johnson/Centocor, Malvern, PA, USA
PSY53 None
PSY54 Grunenthal GmbH, Aachen, Germany
PSY55 None
PSY56 GlaxoSmithKline, London, UK; Human Genome Sciences, Rockville, MD, 
USA
PSY57 Eli Lilly & Co., Indianapolis, IN, USA
PSY58 Federal Ministry of Education and Research, Berlin, Germany
PSY59 None
PSY60 JRDS ePharma Health, Delhi, India
PSY61 None
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PSY63 Actelion Pharmaceuticals, Allschwil, Switzerland
PSY64 Amgen S.A., Barcelona, Spain
PSY66 Covance, Gaithersburg, MD, USA
PSY67 GlaxoSmithKline, Research Triangle Park, NC, USA
PSY68 ANRS, Paris, France
PUK1 None
PUK2 Baxter Healthcare Corporation, Deerﬁ eld, IL, USA
PUK3 Novartis Pharmaceuticals, East Hanover, NJ, USA
PUK4 Wyeth Pharmaceuticals Korea, Seoul, South Korea
PUK5 None
PUK6 None
PUK7 Shire Pharmaceuticals, Wayne, PA, USA
PUK8 Novartis, Mexico, Mexico
PUK9 F. Hoffmann-La Roche Ltd., Basel, Switzerland
PUK10 None
PUK11 Baxter Healthcare Corporation, Deerﬁ eld, IL, USA
PUK12 Bristol-Myers Squibb, Braine l’Alleud, Belgium
PUK13 GlaxoSmithKline, Marly le Roi, France
PUK14 None
PUK15 Baxter, Brussels, Belgium
PUK16 None
PUK17 Baxter Healthcare Corporation, Braine l’Alleud, Belgium
PUK18 None
PUK19 Novartis, Mexico, Mexico
PUK20 Shire Pharmaceuticals, Wayne, PA, USA
PUK21 Wyeth Pharmaceuticals Korea, Seoul, South Korea
PUK22 Abbott GmbH & Co. KG, Wiesbaden, Germany, Wiesbaden, Germany
PUK23 Vzw Wevenef, Antwerpen, Belgium
PUK24 Amgen Europe GmbH, Zug, Switzerland
PUK25 None
PUK26 Shire Pharmaceuticals plc., Wayne, PA, USA
PUK27 F. Hoffmann-La Roche Ltd., Basel, Switzerland
PUK28 Bristol-Myers Squibb, Braine l’Alleud, Belgium
PUK29 Bristol-Myers Squibb, Bruxelles, Belgium
PUK30 Pﬁ zer Spain, Madrid, Spain
PUK31 Pﬁ zer Spain, Madrid, Spain
PUK32 Astellas Pharma Global Development—EU, Leiderdorp, The 
Netherlands
PUK33 Astellas Pharma Global Development—EU, AC Leiderdorp, The 
Netherlands
PUK34 Pﬁ zer Spain, Madrid, Spain
PUK35 PFSA, Boulogne, France
RS1 None
RS2 IHS, Denver, CO, USA
RS3 None
RS4 None
VA1 GSK Bio, Wavre, Belgium
VA2 None
VA3 None
VA4 NUFFIC, Den Haag, The Netherlands
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